Melissa Hollo: The Hidden Burden of Anemia in Cardiovascular Disease
Melissa Hollo, Director of Project Management at hc1 and Licensed Independent Clinical Social Worker, shared Jordan Agay‘s post on LinkedIn, adding:
“Excellent post by Jordan Agay highlighting an often-overlooked clinical reality: Anemia and heart failure are not separate conditions they frequently fuel one another.
Too often, anemia is treated as a standalone lab value rather than a significant contributor to worsening cardiovascular outcomes.
Reduced oxygen-carrying capacity increases cardiac workload, accelerates disease progression, and can negatively impact quality of life, hospitalizations, and mortality.
The challenge is that anemia often develops gradually and can be missed until patients are already experiencing significant symptoms or decompensation.
This is why I appreciate Jordan Agay continuing to raise awareness around the importance of blood health in chronic disease management. Managing heart failure effectively requires looking beyond the heart itself and understanding the whole patient.
Early identification of anemia and iron deficiency provides an opportunity to intervene sooner, improve outcomes, and potentially reduce avoidable complications.
Thank you, Jordan Agay, for keeping the spotlight on this important intersection of cardiovascular care and blood health. These conversations help move healthcare from reactive treatment toward proactive patient management.”
Jordan Agay, Public Health and Bioinformatics Student at The George Washington University and Clinical Product Strategy and Feedback Intern at hc1, shared a post on LinkedIn:
“Heart failure and anemia share more than a patient population. They share a feedback loop. Anemia forces the heart to work harder to compensate for reduced oxygen-carrying capacity.
Over time, that compensatory strain accelerates cardiac remodeling, worsens ejection fraction, and increases heart failure mortality risk. Because both conditions often develop gradually, the convergence point is frequently missed until the patient is already in crisis.
Managing heart failure well requires managing the whole patient. That includes blood health.
In most health systems, anemia in cardiac patients is addressed episodically. A hemoglobin noted here, an iron study missed there. There is no continuous picture of how a patient’s hematologic status is trending alongside their cardiac trajectory.
I’ve had the opportunity to see how hc1‘s Clinical IQ Anemia Management Module changes that.
By synthesizing longitudinal lab data including hemoglobin and iron levels, it gives care teams the visibility to identify and address anemia before it compounds an already complex cardiac problem.”

Stay updated with Hemostasis Today.
-
Aug 11, 2026, 11:47Rucha Patil: Strengthening Evidence-Based Haemophilia Care Across India
-
Aug 11, 2026, 11:38Maria Hadjidemetriou: The Patient Perspective in Thalassemia Care
-
Aug 11, 2026, 11:04Wolfgang Miesbach: The Critical Need for Tailored Dosing in VWD
-
Aug 11, 2026, 08:20Hasan Abbas Zaheer: Strengthening Universal Access to Safe Blood in Pakistan
-
Aug 11, 2026, 08:07Nicola Pozzi: Advancing Hemostasis Through Scientific Collaboration at Hemostasis GRC
-
Aug 11, 2026, 07:50When Access to Care Changes Everything – WFH
-
Aug 11, 2026, 07:41Kevin Land: How Cellular Therapy Is Changing Transfusion Medicine
-
Aug 11, 2026, 07:35Kuldeep Singh Bhadauria: Building the Future of Hemophilia Care in India
-
Aug 11, 2026, 07:28Archil Jaliashvili: When Every Minute Matters Time Becomes a Therapy